Strategies to improve drug development for sepsis

@article{Fink2014StrategiesTI,
  title={Strategies to improve drug development for sepsis},
  author={M. Fink and H. S. Warren},
  journal={Nature Reviews Drug Discovery},
  year={2014},
  volume={13},
  pages={741-758}
}
Sepsis, a common and potentially fatal systemic illness, is triggered by microbial infection and often leads to impaired function of the lungs, kidneys or other vital organs. Since the early 1980s, a large number of therapeutic agents for the treatment of sepsis have been evaluated in randomized controlled clinical trials. With few exceptions, the results from these trials have been disappointing, and no specific therapeutic agent is currently approved for the treatment of sepsis. To improve… Expand
Could Biomarkers Direct Therapy for the Septic Patient?
Sepsis: a roadmap for future research.
Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?
Sepsis: pathophysiology and clinical management
Potential Immunotherapeutics for Immunosuppression in Sepsis
Neutrophil dysregulation during sepsis: an overview and update
Septic Shock
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 225 REFERENCES
Animal models of sepsis
Animal models of sepsis and its complications.
  • M. Fink
  • Medicine
  • Kidney international
  • 2008
Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View
Preclinical sepsis models.
...
1
2
3
4
5
...